Jeff Yass’s Cardiol Therapeutics CRDL Stock Holding History

Jeff Yass’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-41,800	Closed	-$77K	–	13096
2021 Q4	$77K	Buy	+41,800	New	+$115K	﹤0.01%	12307

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CRDL Position: Q2 2026 in Review

Jeff Yass sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 70,396 shares — an estimated $89.1K sold.

Jeff Yass first reported a position in CRDL in Q1 2022 and held it in 13 quarters. The position peaked at $194K in Q4 2025. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Jeff Yass reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 70,396 Cardiol Therapeutics shares in Q2 2026, an estimated $89.1K.
Jeff Yass first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 13 quarters.
Jeff Yass's Cardiol Therapeutics position peaked at $194K in Q4 2025.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.